CAMBRIDGE, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has issued an additional 757,575 shares of common stock at the public offering price of $49.50 per share, for total gross proceeds of approximately $37 million, pursuant to the exercise in full of the underwriters’ over-allotment option in connection with the company’s previously announced public offering of common stock. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Agios in the public offering was 5,808,080 shares and gross proceeds were approximately $287 million.

J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as joint book-running managers for the offering. Cowen and Company, LLC served as lead manager.

About Agios Pharmaceuticals, Inc. 

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.